Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) - previously OTC:TTNP - is a biopharmaceutical company developing proprietary therapeutics primarily for treatment of central nervous system (CNS) disorders. Titans innovative drug delivery platform - ProNeura®, - is advancing treatment of select chronic diseases by delivering low-dose, non-fluctuating medication levels for up to one year following a single subdermal insertion procedure. Titans innovative drug delivery platform - ProNeura® - is advancing the treatment of select chronic diseases by delivering low-dose, non-fluctuating medication levels for up to one year following a single subdermal insertion procedure. Company had been focused on clinical development of: Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders; and Spheramine for the treatment of advanced Parkinsons disease.Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinsons disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders. Interesting also to note that firm has considerable NIH financial support (post 2011) for projects that are NOT SBIR funded.
